Recent News

Dual PI3Kδ/CK1ε Inhibition on CLL T Cells

Predictors of Outcome in Patients with CLL and COVID-19

Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?

CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?

Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma

Two Decades of Data Confirm Poor Prognosis With Richter Transformation in CLL

EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL

EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?

Real-World Study Finds VHA Adopts Novel Agents in CLL Treatment

AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL

EHA25 Virtual: First-Line Ibrutinib/Venetoclax Combination in CLL

EHA25 Virtual: Trial Update on Ibrutinib Plus Umbralisib in Resistant CLL

ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL

EHA25 Virtual: Long-Term Results With Acalabrutinib in Treatment-Naive CLL

ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL

EHA25 Virtual: VENICE-I Findings With Venetoclax in Resistant CLL

EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL

ASCO20: Does Early Discontinuation of Venetoclax Affect Outcomes in CLL?

ASCO20: Cirmtuzumab Plus Ibrutinib in Relapsed or Refractory CLL

ASCO20: Final Results From ASCEND Trial of Acalabrutinib in Resistant CLL

ASCO20: Intermittent Scheduling of PI3Kδ Inhibitor in CLL

Chemotherapy-Free Treatment of CLL: Acalabrutinib With or Without Obinutuzumab

Managing CLL During the COVID-19 Pandemic: An International Survey of Experts

Ofatumumab Treatment and Rare Viral Infection of the Brain : A Case Study in CLL

Brazilian Task Force Offers Strategies for Managing COVID-19 and Lymphoid Malignancies

CLL-Related Cognitive Function: Disease Biology or Treatment Effect?

COVID-19 and Untreated Patients With CLL: Case Reports Shed Light on Clinical Risks

Mitochondrial Respiration: A Prognostic Marker of Response to CLL Treatment?

First-Line Ibrutinib Treatment of CLL: 5-Year Follow-up Results

FDA Approves Ibrutinib Plus Rituximab as Initial Treatment of CLL

Health-Related Quality of Life for Patients With CLL Treated With Ibrutinib

Do Longer Reads Equal Better Reads in Analyzing SF3B1 Mutation in CLL?

COVID-19 Infection Reported in Chinese Patient With CLL

Cellular Polarization and Its Impact on Growth of CLL Cells

Venetoclax Therapy and Attainment of Undetectable Minimal Residual Disease in CLL

Machine Modeling as a Predictive Tool for Infection Risk in Patients With CLL

First-Line Treatment With Four-Drug Regimen in Young Patients With CLL

Genomic Analyses May Predict Treatment Outcomes in Patients With CLL

CAPTIVATE Trial of First-Line Ibrutinib Plus Venetoclax in CLL